XTX Topco Ltd Takes Position in Embecta Corp. (NASDAQ:EMBC)

XTX Topco Ltd bought a new position in Embecta Corp. (NASDAQ:EMBC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,511 shares of the company's stock, valued at approximately $630,000. XTX Topco Ltd owned approximately 0.05% of Embecta at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Embecta by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 7,025,483 shares of the company's stock valued at $145,076,000 after purchasing an additional 28,031 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Embecta by 8.0% during the fourth quarter. American Century Companies Inc. now owns 3,261,934 shares of the company's stock worth $67,359,000 after acquiring an additional 242,668 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Embecta by 3.4% during the third quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company's stock worth $19,564,000 after acquiring an additional 45,228 shares in the last quarter. William Blair Investment Management LLC purchased a new stake in shares of Embecta during the fourth quarter worth $15,270,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Embecta by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company's stock worth $14,155,000 after acquiring an additional 4,769 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company's stock.

Analyst Ratings Changes

Separately, Mizuho started coverage on shares of Embecta in a research report on Thursday, April 10th. They set a "neutral" rating and a $15.00 target price on the stock.

Embecta Price Performance

Shares of EMBC stock traded up $0.49 during trading hours on Thursday, hitting $11.73. 57,614 shares of the company's stock were exchanged, compared to its average volume of 454,074. Embecta Corp. has a 52 week low of $10.00 and a 52 week high of $21.48. The stock has a market cap of $681.74 million, a price-to-earnings ratio of 11.73, a price-to-earnings-growth ratio of 0.78 and a beta of 1.23. The stock's 50-day moving average is $12.83 and its 200-day moving average is $15.83.

Embecta (NASDAQ:EMBC - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. Equities research analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were issued a dividend of $0.15 per share. The ex-dividend date was Friday, February 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.12%. Embecta's payout ratio is presently 60.00%.

Insider Buying and Selling

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the sale, the director now directly owns 36,133 shares in the company, valued at $591,858.54. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.42% of the stock is owned by corporate insiders.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.